---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-063416"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2022-10-12T23:59:59+00:00"
generated_at: "2026-06-23T04:09:37.213879+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401

## Summary
- Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.
- CIP-137401 is a macrocyclic MEK inhibitor for NF1 and Noonan syndrome; already has FDA orphan-drug designation for NF1.
- Plans to file IND in 2H 2023 and initiate Phase 1 trial in NF1; expects synergies with existing MS program.
- Daniel Schneiderman appointed CFO effective Oct 11, 2022 with base salary $330K and 300K stock options.
- Sellers subject to two-year lock-up; 1.35M shares lock up release at one year, then 112.5K monthly.

## SEC filing metadata
- accession: 0001213900-22-063416
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2022-10-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/0001213900-22-063416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/ea167014-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-063416
- JSON: https://secwatch.observer/filing/0001213900-22-063416.json
- Plain text: https://secwatch.observer/filing/0001213900-22-063416.txt

## Key facts
- Executive change
  Daniel Schneiderman was appointed as Chief Financial Officer at Pasithea Therapeutics Corp..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/0001213900-22-063416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.